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The vomeronasal system is one of several fine-tuned scent-detecting signaling systems in mammals.
However, despite significant efforts, how these receptors detect scent remains an enigma. One reason is the
lack of sufficient purified receptors to perform detailed biochemical, biophysical and structural analyses.
Here we report the ability to express and purify milligrams of purified, functional human vomeronasal
receptor hVN1R1. Circular dichroism showed that purified hVN1R1 had an alpha-helical structure, similar
to that of other GPCRs. Microscale thermophoresis showed that hVN1R1 bound its known ligandmyrtenal
with an EC50 ,1 mM. This expression system can enable structural and functional analyses towards
understanding how mammalian scent detection works.
A
lthough the existence and function of a human vomeronasal organ (VNO) is controversial, almost all
studies agree that a vomeronasal organ is present in the developing fetus. However, many studies report
that this organ is vestigial, and function is lost in adults, while others report development of a mature
organ1–6. Interestingly, one study found that the ability to detect the adult vomeronasal organ varies; they could
not find vomeronasal organs in subjects that had clearly identifiable vomeronasal organs on prior inspections,
and vice versa1.
In most mammals, signals from the vomeronasal organ are directed to the accessory olfactory bulb (AOB).
However, studies in humans suggest that degenerative changes occur in the fetal accessory olfactory bulb, and that
it isn’t present in adults4,5. Most studies that used neuron-specific stains failed to find evidence of nerve bundles1,6.
Others suggest the presence of neurons in the adult vomeronasal organ, albeit at a low density7. In spite of
this, some studies suggest pheromonal responses in humans directly through the vomeronasal organ.
Androstadienone applied directly to the female vomeronasal organ decreased nervousness, tension, and negative
feeling states. Decreases in cardiac frequency and respiratory frequency, and increases in body temperature and
alpha-coritcal activity were alsomeasured8.When a steroidal vomeropherin was applied to themale vomeronasal
organ, a decrease in follicle-stimulating hormone and luteinizing hormone pulsatility was observed. Changes in
cardiac frequency, respiratory frequency, and other physiological responses were also observed9.
Taken together, current evidence suggests that humans may have a potentially functional vomeronasal organ
that functions differently than in other mammals. However, until recently, it was believed that human vomer-
onasal receptors (VNRs) were all pseudogenes. In 2002, Rodriguez andMombaerts found 5 VNR type 1 (VN1R)
genes with open reading frames. They were successfully expressed in HeLa/Olf cells11. Interestingly, all five were
found to respond to volatile molecules and signal through the canonical olfactory signaling pathway. Even more
curiously, mRNA of one receptor – hVN1R1 – was detected in several other tissues, including the main olfactory
epithelium (MOE), brain, lung, and kidney12. This raises the possibility that human VN1Rs may function more
like olfactory receptors in the MOE, or may have non-olfactory functions.
Studying human vomeronasal receptors at themolecular level may shed light on both their function and that of
the human vomeronasal organ. However, the difficulty of functionally expressing and purifying these G-protein
coupled receptors in sufficient quantities is a major obstacle towards research. Only one report has produced
functional receptors in cells, and identified potential ligands11. However, in order to study their structure and
function, it is necessary to produce and purify milligram-scale quantities. Here, we report a method of expressing
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and purifying milligram-level quantities of the human receptor
hVN1R1 from HEK293 cells. Circular dichroism indicated that the
purified receptor was properly folded with stable a-helical domains.
Microscale thermophoresis assays showed that the purified receptor
was able to bind to its ligand. Our expression platform provides the
basis for carrying out further structural analyses of the human
vomeronasal receptors, and can enable screens for crystallization
trials. It could not only aid in future studies of human VNRs and
help identify their biological role, it could also provide a basis for
designing biologically inspired devices like artificial noses.
Results
Induction of hVN1R1 expression in stable HEK293 cell lines.
Producing milligram quantities of homogenous membrane protein
samples is notoriously difficult. Over-expression of these proteins in
mammalian cells is often reported to have toxic effects, which reduce
the total protein yield. Additionally, constitutive expression of such
proteins yields non-homogeneous samples, as proteins can be in
various stages of synthesis, degradation, or post-translational
modification. To minimize toxic effects, and to generate a
homogenous protein sample, the Invitrogen T-REx system was
used to create stable hVN1R1- inducible cell lines13. This system
allows large batches of cells to be grown and simultaneously
induced to express protein.
Sodiumbutyrate has previously been used to enhance tetracycline-
regulated protein expression13,14. Induction of VN1R1 expression
was thus tested with tetracycline alone, and tetracycline combined
with sodium butyrate at various concentrations. No detectable pro-
tein expression was seen in the absence of induction agents. Sodium
butyrate combined with tetracycline enhanced protein expression
4–5 fold over induction with tetracycline alone. Significant cell death
was observed in cultures treated with both tetracycline and sodium
butyrate, indicating the toxic effects of protein expression. The clone
with the highest expression, the least toxicity, and least degradation
products was selected and expanded. For all subsequent experiments,
the following induction condition was used: 1 mg/ml of tetracycline
and 2.5 mM of sodium butyrate for 48 hours.
SDS-PAGE andWestern blotting analysis were used to character-
ize the protein samples. Immunoblotting against the rho1D4 tag
revealed two bands, which correspond in size to monomeric and
dimeric forms of the receptor. This size pattern has been reported
for several olfactory receptors13,15,16, and is the first such reporting for
a human vomeronasal receptor. The hVN1R1 sample also showed
evidence of a degradation product.
Immunohistochemical staining of induced cells. Numerous
studies report the difficulty of expressing GPCRs in heterologous
systems, and particularly of targeting proteins to the membrane17–20.
Glycosylation, particularly of specific conserved N-terminal sites,
may be necessary for proper protein folding and localization21.
However, glycosylation can lead to inhomogeneous samples and
make crystal packing difficult. Here, we used the rho1D4-tagged
protein with potential glycosylation sites removed. To determine
whether removal of predicted glycosylation sites affected protein
localization, induced cells were stained with antibodies against the
rho1D4 tag. (Figure 1) Non-induced cells showed negligible
fluorescence. Permeabilized cells stained with the rho1D4 tag
demonstrated membrane-localization of the protein. These results
indicate that the protein is trafficked to the cell membrane. They
further demonstrate that the hVN1R1 glycosylation sites are not
necessary for appropriate protein localization in HEK293 cells,
and indicate that they are not necessary for appropriate protein
folding.
Systematic detergent screening for receptor solubilization.
Selection of an appropriate detergent is critical for the successful
solubilization of a GPCR from a cell membrane, and for the
subsequent purification and stabilization of the receptor. Since the
optimal detergent can vary even between proteins in the same family,
it must be empirically determined. Thus, we carried out a systematic
detergent screen (Figure 2).
Ninety-six detergents were screened. These detergents belonged to
one of four general classes: anionic, cationic, non-ionic, and zwitter-
ionic. The detergents were chosen from a commercial Solution
Master Detergent Kit22, and included detergents that have been
successfully used to purify, solubilize, or crystallize GPCRs.
Additionally, several detergent mixtures were tested as previously
described22. All detergents were used at a concentration of 2%, which
was above the critical micelle concentration, with the exception of
MEGA-8.
The most effective detergents for hVN1R1 solubilization were
the zwitterionic fos-choline series (#71–78) and n-Dodecyl
B-iminodpropionic acid (DIPA, #89). The zwitterionic cyclofos-
7, cationic hexadecyl- and tetradecyltrimethylammonium chlor-
ide detergents (#8, 9), and anionic sodium dodecanoyl sarcosine
(#5) were also reasonably effective, while most other detergents
failed to solubilize a significant amount of receptor. Similar
results with other GPCRs have previously been reported22,23.
The effectiveness of the fos-choline (FC) series to solubilize mem-
brane proteins is not surprising: they are structurally related to
phosphatidylcholine, a constituent of the phospholipid bilayer.
Although FC15, FC16, and DIPA were able to solubilize more
protein, FC14 was chosen for all subsequent experiments. The
CMC for DIPA has not been established, and FC15 and FC16
Figure 1 | Immunohistochemical staining of hVN1R1. (a) Non-induced
HEK293 cells showed no staining. (b) Induced HEK293 cells stained with
the rho1D4 antibody showed that the expressed hVN1R1 was localized to
the cell membrane.
Figure 2 | Detergent screens for solubilizing and stabilizing hVN1R1.
Zwitterionic detergents typically solubilized a greater portion of the
expressed protein, though several cationic and anionic detergents were able
to solubilize significant amounts. The fos-choline detergents were the sub-
class of detergents that solubilized the greatest amount of protein.
www.nature.com/scientificreports
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have much lower CMCs, which could inhibit detergent substi-
tution in downstream experiments. Furthermore, previous
experiments indicate that the fos-choline family may promote
proper folding as well as stabilize the protein structure24.
Additionally, FC14 has previously been used for membrane pro-
tein solubilization and purification13,22,23,25, and has been used to
crystallize and solve two high-resolution protein structures26,27.
Purification of HEK293-expressed hVN1R1. A two-step process
using immunoaffinity chromatography and size-exclusion
chromatography (SEC) was used to purify the expressed VN1R1
receptors (Figure 3)13,23.
A small-scale purification was performed to determine the potential
of using heterologous expression for large-scale protein production.
Solubilized protein was first bound to rho1D4-tagged Sepharose 4B
beads. After thoroughly washing the column to remove impurities, the
protein was eluted with an excess of the rho1D4 epitope peptide Ac-
TETSQVAPA-NH2. To further purify the protein, remove the elution
peptide, and separate the monomeric and dimeric forms, the receptor
sample was subjected to SEC. The column flow through wasmonitored
with UV absorption at 280 nm and 215 nm, and was automatically
collected in separate fractions. The UV spectrum showed 4 distinct
peaks. The fractions corresponding to these peaks were pooled, con-
centrated, and analyzed by western blotting and silver staining. The
first two peaks primarily corresponded to dimerized and aggregated
protein, though the monomeric form was present throughout. The
third peak corresponded to the monomeric form, which could be
obtained at .90% purity. The fourth peak was the elution peptide
(Figure 3). Western blotting and total protein stains demonstrated that
all of the expressed receptors had been captured by the beads. One
gram of cells yielded approximately 1 mg of total protein. Of the
protein recovered after SEC, over 60% was the monomer. These yields
are sufficient to obtain large quantities of highly pure receptor for
biochemical analyses and crystal screens. Bioreactor suspension cul-
tures could also potentially be used to increase the protein yield23.
Structural characterization of purified hVN1R1. Circular
dichroism (CD) was used to determine whether the FC14-solubilized
and purified hVN1R1 was properly folded (Figure 4). Far and near UV
were used to probe the secondary and tertiary structure of the purified
receptor. Figure 4A shows the far UV spectrum. The CD spectrum
showed a characteristic a-helical shape with valleys at about 208 and
220 nm. This is expected, since hVN1R1 is a GPCR with 7 predicted
transmembrane helices. Figure 4B shows the near UV spectrum. The
peaks in the near UV spectrum indicate that the purified VN1R1 has a
well-defined tertiary structure23,28. Together, the CD spectra suggest
that HEK293-expressed hVN1R1 is properly folded, and that FC14
is able to maintain this structure once the receptor has been
extracted from the cell membrane and purified.
Ligand binding assay of purified hVN1R1. Microscale
thermophoresis (MST) was used to determine whether the FC14
solubilized receptor could bind its ligand myrtenal (MW 152.23).
MST is the directed movement of molecules along a spatial
temperature gradient. This movement is sensitive to changes in the
hydration shell surrounding the molecule. Ligand-binding alters
this shell in a way that measurably changes the molecules’
thermophoretic movement29–31. MST yields results that are com-
parable to SPR and other binding assays32. However, unlike SPR or
other surface-based techniques, MST does not require immobiliza-
tion. The molecules are monitored in free solution. Additionally,
proteins can be tracked by detecting the fluorescence of native
tryptophans. Coupling-chemistries or other modifications that
could potentially alter a receptors’ function are thus not necessary.
The purified monomeric form of hVN1R1 was used for ligand-
binding measurements. Samples were titrated with varying concen-
trations of myrtenal. Myrtenal has been reported as a ligand with an
expected EC50 of ,22 mM in HeLa/Olf cells11. Figure 5 shows the
MST titration curves normalized to the fraction of bound receptor.
The monomer exhibits a plateau at low concentrations and at high
concentrations. Fitting the Hill equation to the data yields a KD of
,1 mM.This result is similar to the result reported by Shirokova et al,
and is also in the same range as KD values measured for olfactory
receptors23,33. Boiled controls under otherwise identical conditions
did not exhibit any plateaus, demonstrating that the measured
changes in thermophoretic amplitude resulted from myrtenal bind-
ing to hVN1R1. Future studies must be performed to determine the
effect dimerization has on hVN1R1 function.
Discussion
Our study shows that HEK293 cells can be used to producemilligram
quantities of a human vomeronasal receptor. The purified receptors
had alpha-helical secondary structures, suggesting that they were
properly folded. They were also able to bind their reported small
molecular ligand, and the measured EC50 value is in agreement with
what has have been previously reported.
A growing body of evidence suggests that HEK293 cells are a
suitable platform for expressing GPCRs. HEK293 cells have success-
fully been used to produce rhodopsin and the olfactory receptor
hOR17-413,14,23. All of the tested cultures yielded large quantities of
receptors that could be easily purified using the rho1D4 epitope and
monoclonal antibody. Our study further showed that removal of
predicted glycosylation sites does not inhibit membrane localization
or ligand binding. Although our study only used cells grown on tissue
culture plates, previous reports have shown that HEK293 cells can be
grown in suspension to yield even larger quantities of receptors23.
Because the optimal detergent for a givenmembrane protein must
currently be determined empirically, finding a detergent that can
stabilize a class of membrane proteins would be an important con-
tribution. This would save time and resources, and also shorten the
path towards studying more membrane proteins. Our results con-
tribute to a growing body of evidence that FC14 may be a promising
detergent for stabilizing diverse GPCRs. In addition to hVN1R1, it
has solubilized and stabilized various other GPCRs, including several
Figure 3 | Silver stain of hVN1R1. Four distinct peaks were observed on
the 280 nm UV trace through a size exclusion column (SEC). Samples
corresponding to the peaks were pooled and run on a gel. The first peak
(lane 1) primarily corresponded to higher molecular weight aggregates.
The second peak (lane 2) contained dimerized receptor. The third peak
(lane 3) contained a monomeric version of hVN1R1. This form of the
receptor constituted over 60% of the protein recovered after SEC, and
was present in all of the samples. The fourth peak contained the elution
peptide, and is not shown.
www.nature.com/scientificreports
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chemokine receptors (CCR3, CCR5, CXCR4, CX3CR1), and several
olfactory receptors13,22,25. Although FC15 and FC16 were able to
solubilize a greater quantity of expressed receptor than FC14, all
three detergents were able to solubilize comparable amounts. Since
FC14 has a CMC that is high enough to allow for detergent exchange,
has been used to obtain high resolution protein structures26,27, and
can be used for both the solubilization and purification processes, it
appears to be a promising choice in membrane protein studies.
Figure 4 | Circular dichroism spectra of purified hVN1R1. (a) Far UV trace showing a curve characteristic of an alpha-helix. This shape is expected, as
hVN1R1 is a GPCR with seven predicted transmembrane helices. (b) Near UV trace. The peaks indicate that the protein has a well-defined tertiary structure.
Figure 5 | Ligand binding assay of purified hVN1R1 using micro-scale thermophoresis. (a) Samples of hVN1R1 were titrated against varying
concentrations of myrtenal, and its thermophoretic mobility was measured. The plateaus at low and high myrtenal concentrations indicate that
the receptor is binding its ligand with an EC,1mM. (b) A boiled control did not exhibit the characteristic sigmoidal binding curve, indicating
that the assay was indeed measuring binding between hVN1R1 and myrtenal. Measurements were performed in triplicate.
www.nature.com/scientificreports
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Our experimental results suggest that humans have functional
VNR genes, while previous reports suggest that human VN1Rs
may function more like olfactory receptors. This is the first report
showing direct binding between a vomeronasal receptor and a vol-
atile ligand. Our study and previous reports show that they bind
volatile molecules with mM binding affinities11, they can couple to
the canonical OR signaling pathway via Gaolf and Gas and cAMP11,
and hVN1R1 mRNA has been detected in the human MOE12.
Indeed, mouse VN1Rs signal through TRP, which is a pseudogene
in humans. If human VN1Rs are biologically functional, they must
have a different signalingmechanism that still needs to be elucidated.
TheHEK293 cells used in this study provide an excellent mechanism
to perform such studies. These cells have been successfully used to
express and purify other GPCRs including the olfactory receptor
OR17-413,14,23. They can thus be used as a platform to compare OR
and VNR function and signaling. Additionally, although the human
VNO may not be a functional organ, expression of hVN1R1 mRNA
in other tissues in addition to the MOE raises the possibility that it
may have non-olfactory functions. Indeed, OR17-4 functions in both
olfaction and sperm migration34.
Membrane proteins are not only critical for communication
between the cellular and external environments, they also have
potential uses in medicine and the design of biotechnology-based
devices. They comprise nearly 25–30% of genes in the sequenced
genomes, and are involved in various processes ranging from chem-
ical transport, signal transduction, and photosynthesis. GPCRs, the
largest subclass of membrane proteins, are the target of nearly 50% of
pharmaceutical drugs. Olfactory-related proteins (including VNRs)
are the largest subclass of GPCRs, and could potentially be used to
develop highly sensitive detectors.
Detailed structural knowledge of membrane proteins is critical for
developing new technologies and medicines. Yet, in spite of their
enormous potential, very little is known about membrane protein
structures. Of the ,76,000 protein structures known as of October
2011, only 302 are uniquemembrane proteins, and only 6 are unique
GPCRs. To facilitate protein structure determination, fast and reli-
able methods of protein expression and purification must be
developed. In addition to hVN1R1, the methods used in this study
have been successfully used with bovine rhodopsin and OR17-4.
Here, we further show that expressed proteins are functional and
targeted to the membrane even when potential glycosylation sites
have been removed. This further underscores the potential of this
system to be used with a wide variety of membrane proteins in
preparation for crystallization trials. Our efforts to purify hVN1R1
may not only help understand the role and function of the human
vomeronasal system, but could also contribute toward other mem-
brane protein studies and the development of biologically-inspired
technologies like artificial noses.
Methods
hVN1R1 gene design and construction. The protein sequence for hVN1R1 was
obtained from GenBank (AAG10698). To enable expression and purification from
mammalian cells, the following modifications were made: 1) addition of a C-terminal
rho tag (TETSQVAPA) preceded by a two glycine linker; 2) human codon
optimization; 3) addition of a Kozak sequence 59 to the start codon; 4) addition of a 59
EcoRI site and a 39 XhoI site to facilitate subcloning into expression vectors; 5)
addition of an N-terminal strep tag (ASWSHPQFEK) followed by a GSSG linker for
further purification; and 6) N117Q, N151Q, N183Q, N198Q, and N256Q mutations
to facilitate crystallization. The genes were constructed by Geneart and ligated into
the pcDNA 4/To vector (Invitrogen, Carlsbad, CA). The plasmid was amplified in
subcloning efficiency DH5a E. Coli (Invitrogen) and purified using Mini- or
MaxiPrep kits (Quiagen, Valencia, CA). The transmembrane and loop domains were
predicted using the TMHMM Server v 2.0 (http://www.cbs.dtu.dk/services/
TMHMM/). N-linked glycosylation sites were predicted using the NetNGlyc 1.0
Server (http://www.cbs.dtu.dk/services/NetNGlyc/).
Construction of stable inducible hVN1R1 HEK293G cell lines. HEK293S
N-acetylglucosaminyltransferase I-negative cells (HEK293G) containing the
pcDNA6/Tr vector13 were transfected with the pcDNA4/To-hVN1R1 vector using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Forty-eight hours after transfection, selective media containing 5 mg/ml of blasticidin
and 50 mg/ml zeocin was added. Cells were re-seeded at low density and grown until
individual colonies formed. Forty-eight colonies were picked and screened for
inducible hVN1R1 expression. Cells were treated with plain media, media
supplemented with 1 mg/ml tetracycline, and media supplemented with
1 mg/ml tetracycline and 1, 2.5, or 5 mM sodium butyrate. Two days after induction,
cells were scrape-harvested and solubilized in PBS with 2% w/v Fos-Choline 14 (FC-
14) (Anatrace) and protease inhibitors (Roche) for 1 hr at 4uC. Cell lysates were
centrifuged for 30 minutes at 10,000 rpm to remove insoluble debris. Dot blots and
Western-blots were used to compare protein expression among clones. The clone
with the highest expression when induced, the least detectable expression when not
induced, and least toxicity upon induction, was selected and expanded for future
experiments. All cultures were grown in DMEM F12 with GlutaMAX (Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen), 15 mM HEPES
(Invitrogen), 0.1 mM non-essential amino acids (Invitrogen), 0.5 mM sodium
pyruvate (Invitrogen), 100 Units/ml penicillin and 100 mg/ml streptomycin
(Invitrogen). The expanded stable hVN1R1 clone was maintained in media that
also contained 5 mg/ml blasticidin and 25 mg/ml zeocin. All cells were grown at 37uC,
5% CO2, and 95% relative humidity.
Immunocytochemistry. Vomeronasal receptors were visualized using a rho1D4
primary antibody. Cells were seeded at low density on poly-L-lysine (Sigma-Aldrich)
coated glass coverslips. After one day, cells were induced with 1 mg/ml tetracycline
and 1 mM sodium butyrate. One day after induction, the media was removed. Cells
were gently washed with PBS and fixed for 20 minutes in 10% neutral buffered
formalin (Sigma-Aldrich) at room temperature. Permeabilized (151
acetone:methanol, 3minutes,220uC) and non-permeabilized cells were then blocked
in PBST (PBS, 0.2% tween-20, 0.3 M glycine, 4% serum) for 1 hour at room
temperature, and incubated with the primary antibody solution (151500, PBS, 0.2%
tween-20, 4% serum) overnight at 4uC. The labeled protein was visualized with Alexa-
flour-488 goat-anti-mouse secondary antibody conjugate (153000, PBS, 1 hour,
room temperature). Slides were mounted using ProLong Gold Antifade with DAPI.
Cell extract preparation.Cells were grown on plates as previously described13.When
the appropriate density was reached, cells were inducedwith 1 mg/ml tetracycline and
1 mMsodiumbutyrate. Two days after induction, cells were scrape harvested, pooled,
snap frozen in liquid nitrogen, and stored at280uC until used for future experiments.
Detergent Screening. Frozen cell pellets were thawed on ice and resuspended in
PBS containing protease inhibitors (Roche). Detergents were added to a final
concentration of 2%w/v. The suspensions were rotated for 1 hour at 4uC to solubilize
the protein, and were spun at 13,000 rpm for 30 minutes to remove insoluble
fractions. Relative protein solubilization in each detergent was assayed with a dot blot.
Ninety-six detergents were selected for screening as previously described22.
Receptor purification. Rho1D4 immunoaffinity purification has been previously
described13,23. Briefly, frozen cell pellets were thawed on ice. Cells were resuspended in
PBS containing protease inhibitors. PBS containing FC-14 was added to a final
concentration of 2% w/v FC-14. The final liquid:cell ratio was 12.5 ml/1 g cells. The
protein was solubilized by rotating for 4 hours at 4uC. The non-solubilized fraction
was pelleted by centrifuging for 30 minutes at 30,000 g at 4uC. The solubilized
fraction was incubated with DNAse (152000) and RNAse (151000) for 15minutes on
ice. Rho1D4-coupled CNBr-activated Sepharose 4B beads (GE Healthcare) were
added to the cell extract supernatant (binding capacity 0.7 mg/ml); receptors were
captured by rotating the mixture overnight at 4uC. The beads were collected by
centrifuging at 1400 rpm for 1 minute, or filtering the supernatant through a filter
column (Biorad). The supernatant was saved for future analysis and labeled as ‘‘flow-
through’’. The beads were resuspended in 1 bead volume of wash buffer (PBS1 0.2%
w/v FC-14), rotated for 10 minutes at 4uC, and re-pelleted. Washes were performed
until the total protein concentration in the washes was less than 0.01 mg/ml
(NanoDrop). One bead volume of elution buffer (PBS10.2% w/v FC-14 1 200 uM
Ac-TETSQVAPA-NH2 peptide) was then added to the beads. Elutions were
performed until the total protein concentration was less than 0.01 mg/ml.
Size exclusion chromatography was used to separate the monomeric and higher
molecular-weight forms of the receptor. A Hi-Load 16/60 Supradex 200 column with
an Akta Purifier HPLC system (GE Healthcare) was used. The column was first
equilibrated with at least 1 column volume of wash buffer. Protein samples were
concentrated to 1.5-3 ml using a 50,000 MWCO filter column (Millipore), loaded on
the column, and run with wash buffer at 0.3 ml/min. Fractions exiting the column
were automatically collected; protein content was monitored with UV absorbance
at 215 nm, 254 nm, and 280 nm. Peak fractions were pooled, concentrated, and
analyzed with Western blotting and silver staining (SilverXpress, Invitrogen). A
calibration to correlate the column exit time with the molecular mass was
previously performed in our lab, and is described in [23].
GPCR Detection and Purity Analysis. Western blots and silver stains were used to
detect the proteins and analyze their purity. Samples were prepared and loaded in
Novex 10% Bis-Tris SDS-PAGE gels (Invitrogen) according to the manufacturer’s
protocol, with the exception that the samples were incubated at room temperature
prior to loading as boiling causes membrane protein aggregation. For blotting, the
gel-resolved samples were transferred to a nitrocellulose membrane, blocked in milk
(5% w/v non-fat dried milk in TBST) for 1 hour, and incubated with a rho1D4
www.nature.com/scientificreports
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primary antibody (153000 in TBST, 1 hour at room temperature, or overnight at
4uC). The GPCRs were then detected with a goat anti-mouse HRP-conjugated
secondary antibody (Pierce, Rockford, IL) (155000 in TBST, 1 hour, room
temperature) and visualized using the ECL-Plus Kit (GE Healthcare). The
SilverXpress kit (Invitrogen, LC6100) was used according to the manufacturer’s
instructions to perform total protein stains of the samples. All images were captured
using a Fluor Chem gel documentaion system (Alpha Innotech, San Leandro, CA).
ImageJ software [27, 28] was used to compare band intensities and analyze sample
purity.
Circular Dichroism Spectroscopy. Far UV CD spectra were measured over the
wavelengths 200 nm–260 nm with a CD spectrometer (AVIV Biomedical Model
202). Measurements were made at 15uC, with a step size of 1 nm and an averaging
time of 4 seconds. Measurements for each sample were made in triplicate and
averaged. Protein samples were concentrated to at least 0.1 mg/ml for far UV
readings, and 1.7 mg/ml for near UV readings; concentrations were determined by
averaging ten spectroscopic measurements (Nanodrop). The protein spectra were
blanked to the spectrum obtained for wash buffer. A QS quartz cuvette (Hellma) with
a 1 mm path length was used to perform all experiments.
Microscale Thermophoresis Ligand Binding Assay. Thermophoresis was used to
measure the binding interactions between purified receptors and their ligands using a
setup similar to that previously described30,31. To eliminate artifacts caused by labeling
or modifying proteins, the fluorescence of native GPCR tryptophans was used to
monitor the local receptor concentration. For each tested GPCR, a titration series
with constant receptor concentration and varying ligand concentrations was
prepared in a final solution of 10% DMSO and 0.2% FC-14 in PBS. Potential
autofluorescence of each ligand was checked: no fluorescence signal was detected
from the ligands in the tryptophan fluorescence channel. The final receptor
concentration was 2 mM. Approximately 1.5 ml of each sample was loaded in a fused
silica capillary (Polymicro Technologies, Phoenix, USA) with an inner diameter of
300 mm.An infrared laser diodewas used to create a 0.12 K/mMtemperature gradient
inside the capillaries (Furukawa FOL1405-RTV-617-1480, wavelength l51480 nm,
320 mWmaximum power, AMS Technologies AG, Mu¨nich Germany). Tryptophan
fluorescence was excited with a UV-LED (285 nm), and was measured with a 40x
SUPRASIL synthetic quartz substrate microscope objective, numerical aperture 0.8
(Partec, Goerlitz, Germany). The local receptor concentration in response to the
temperature gradient was detected with a photon counter PMT P10PC (Electron
Tubes Inc, Rockaway, NJ, USA). All measurements were performed at room
temperature. Fluorescence filters for tryptophan (F36-300) were purchased from
AHF-Analysentechnik (Tu¨bingen, Germany).
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